Exploring how targeting cell recycling processes can help treat kidney cancer
Targeting Lysosomal Vulnerabilities in Renal Pathogenesis
This study is looking at how a process called autophagy helps kidney cancer cells survive tough times, and it aims to find markers that can help doctors know which patients will do best with treatments that block this process, so they can create more personalized and effective treatment plans just for you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Arizona NIH-funded |
| Lab location | 1 site (Tucson, United States) |
| Project ID | NIH-11051856 on NIH RePORTER |
What this research studies
This research investigates the role of autophagy, a process that cancer cells use to survive under stress, particularly in renal cell carcinoma (RCC). The study aims to identify biomarkers that can predict which patients will respond best to treatments that inhibit autophagy. By focusing on the REDD1 protein, which influences how RCC cells react to these therapies, the research seeks to optimize treatment combinations that include autophagy inhibitors. Patients may benefit from more personalized and effective treatment strategies based on their specific cancer characteristics.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with renal cell carcinoma who may benefit from targeted therapies.
Not a fit: Patients with other types of cancer or those who do not have renal cell carcinoma may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with renal cell carcinoma.
How similar studies have performed: Previous research has shown promising results in targeting autophagy in cancer treatment, suggesting that this approach may be effective.
Where this research is happening
Tucson, United States
- University of Arizona — Tucson, United States (Active)
Researchers
- Principal investigator: Nawrocki, Steffan T — University of Arizona
- Study coordinator: Nawrocki, Steffan T
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.